Abstracts Archive - Page 206 of 1683 - ATC Abstracts

2021 American Transplant Congress
Bamlanivimab for Covid-19 in Kidney Transplant Patients
M. Y. Jan, S. El-Sayegh, M. S. Yaqub, D. P. Mishler, O. Adebiyi, M. D. Anderson, T. E. Taber, A. Sharfuddin
Nephrology, Indiana University School of Medicine, Indianapolis, IN
*Purpose: Treatment options for patients with COVID 19 have limited efficacy in reducing severity and duration of viral symptoms as well as progression to severe…
2021 American Transplant Congress
High Levels of Sars-cov-2 Detected in Immunosuppressed Covid-19 Patient Environments Weeks Following Initial Positive Test
C. E. Kuschner¹, Z. Brune², L. B. Becker¹, L. Teperman¹
¹North Shore University Hospital, Manhasset, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY
*Purpose: COVID-19 is a novel viral illness associated with significantly worse mortality, prolonged disease course, and extended periods of viral shedding in transplant patients on…
2021 American Transplant Congress
Kidney Transplant Biopsy Findings After Covid-19
E. Daniel¹, S. Kudose², D. J. Cohen¹, L. Ratner³, V. D'Agati², I. Batal²
¹Division of Nephrology, Columbia University Medical Center, NY, NY, ²Department of Pathology, Columbia University Medical Center, NY, NY, ³Department of Surgery, Columbia University Medical Center, NY, NY
*Purpose: COVID-19 has been reported as a cause of kidney injury and data from published native kidney biopsy results demonstrate a variety of causes. To…
2021 American Transplant Congress
Short Term Outcomes in Previously Covid Positive Kidney Transplant Recipients in Pre-vaccine Era
R. Prashar, N. J. Khoury, M. Ramesh, A. K. Patel
Henry Ford Transplant Institute, Detroit, MI
*Purpose: To study clinical characteristics and short-term outcomes in kidney transplant recipients who were previously infected with SARS-CoV-2*Methods: In this retrospective, single-center case-series, we identified…
2021 American Transplant Congress
One-Year Monitoring of Changes to Kidney-Pancreas Waiting Time Criteria: An OPTN Analysis
R. C. Forbes¹, B. Plucinski², J. White², N. T. Kyaw², R. Kandaswamy³, S. V. Niederhaus⁴
¹Surgery, Vanderbilt University, Nashville, TN, ²UNOS, Richmond, VA, ³Surgery, University of Minnesota, Minneapolis, MN, ⁴Surgery, University of Maryland, Baltimore, MD
*Purpose: In 2018, the OPTN board approved changes to kidney-pancreas (KP) waiting time criteria. KP candidates accrued waiting time if they were (1) on insulin…
2021 American Transplant Congress
Donor-Derived Cell-Free DNA Can Differentiate Rejection versus Other Causes of Pancreas Transplant Dysfunction
N. Ali¹, J. Miles², Z. Stewart Lewis¹
¹Transplant Institute, NYU Langone Health, New York, NY, ²CareDx, Brisbane, CA
*Purpose: Assessment and early detection of allograft injury in simultaneous pancreas and kidney (SPK) transplant recipients has clear benefits for optimizing treatment and intervention. Donor-derived…
2021 American Transplant Congress
Psychosocial Outcomes 1-year Post Total Pancreatectomy and Autologous Islet Cell Transplant
J. Steel¹, A. Amin¹, M. Wijkstrom¹, A. Zureikat¹, E. Tillman¹, R. Jones¹, D. Yadav¹, A. Slivka¹, A. Phillips¹, M. Bellin², A. Carroll³, A. Humar¹
¹University of Pittsburgh, Pittsburgh, PA, ²University of Minnesota, Minneapolis, MN, ³University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: A paucity of research regarding the psychosocial outcomes after-total pancreatectomy and autologous islet cell transplantation exists. The aim of the study was to examine…
2021 American Transplant Congress
Characterization of SGLT2 Inhibitor Use After Abdominal Transplant
F. Hailemariam¹, S. Yeager², J. Schulte³, P. Singh¹, A. Yadav¹
¹Transplant Nephrology, Thomas Jefferson University Hospital, Philadelphia, PA, ²Abdominal Transplant Pharmacist, Thomas Jefferson University Hospital, Philadelphia, PA, ³Abdominal Transplant, Clinical Pharmacist, Thomas Jefferson University Hospital, Philadelphia, PA
*Purpose: Post solid organ transplantation, diabetic kidney disease (DKD) can progress due to recurrent pre-transplantation diabetes or the development of post-transplantation diabetes mellitus (PTDM). This…
2021 American Transplant Congress
The Impact of Thromboelastography on Decreasing Blood Product Usage in Liver Transplantation
A. Mohamed¹, T. Kitajima¹, S. Angappan², K. Delvecchio¹, A. M. Elsabbagh¹, S. Yeddula¹, M. Shamaa¹, K. Collins¹, M. Rizzari¹, A. Yoshida¹, M. Abouljoud¹, J. El-Bashir², S. Nagai¹
¹Department of Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Department of Anesthesiology, Henry Ford Hospital, Detroit, MI
*Purpose: Liver dysfunction results in derangement of hemostasis and thrombosis. Thromboelastography (TEG) has emerged as a tool to guide resuscitative efforts. However, its utilization and…
2021 American Transplant Congress
Impact of Insulin Therapy in Pancreas Transplantation Donors on Graft Outcomes: An Analysis of the Optn/unos Database
E. Montagud-Marrahi¹, F. Ausania², Y. Fundora², A. Amor³, E. Esmatjes³, J. Ferrer², I. Revuelta¹, D. Cucchiari¹, J. Rovira⁴, M. Musquera⁵, C. Fondevila², F. Diekmann¹, P. Ventura-Aguiar¹
¹Nephrology and Kidney Transplantation Department, Hospital Clinic de Barcelona, Barcelona, Spain, ²Hepatobiliopancreatic and Liver Transplant Department, Hospital Clinic de Barcelona, Barcelona, Spain, ³Endocrinology Department, Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Laboratori Experimental de Nefrologia I Trasplantament (LENIT), CRB CELLEX, Fundació Clínic, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain, ⁵Urology Department, Hospital Clinic de Barcelona, Barcelona, Spain
*Purpose: Hyperglycemia requiring insulin treatment is frequent in critically ill patients and potential pancreas donors. Information on the impact of donor insulin use on pancreas…